Purpose: The hematopoietically active tissues of skeletal bone marrow are a prime target for computational dosimetry given potential risks of leukemia and, at higher dose levels, acute marrow toxicity. The complex three-dimensional geometry of trabecular spongiosa, however, complicates schema for dose assessment in such a way that only a few reference skeletal models have been developed to date, and which are based upon microimaging of a limited number of cadaveric bone spongiosa cores. The question then arises as to what degree of accuracy is achievable from reference skeletal dose models when applied to individual patients or specific exposed populations? Methods: Patient variability in marrow dosimetry were quantified for three skeletal sites -the ribs, lumbar vertebrae, and cranium -for the beta-emitters 45 Ca, 153 Sm, and 90 Y, and the alpha-particle emitters 223 Ra, 219 Rn, and 215 Po, the latter two being the immediate progeny of the former. For each radionuclide and bone site, three patient parameters were altered from their values in the reference model: (1) bone size as a surrogate for patient stature, (2) marrow cellularity as a surrogate for ageor disease-related changes in marrow adiposity, and (3) the trabecular bone volume fraction as a surrogate for bone mineral density. Marrow dose variability is expressed as percent differences in the radionuclide S value given by the reference model and the patient-parameterized model. The impact of radionuclide biokinetics on marrow dosimetry was not considered. Results: Variations in overall bone size play a very minor role in active marrow dose variability. Marrow cellularity is a significant factor in dose variability for active marrow self-irradiation, but it plays no role for radionuclides localized to the trabecular bone matrix. Variations in trabecular bone volume fractions impact the active marrow dose variability for short-range particle emitters 45 Ca, 223 Ra, 219 Rn, and 215 Po in the vertebrae and ribs, skeletal sites with small spongiosa proportions of trabecular bone. In the cranium, with its relative high proportion of trabecular bone, significant differences in marrow dosimetry from the reference model were noted for all radionuclides. Conclusions: Skeletal models of active marrow dosimetry should be more fully parameterized to permit closer matching to patient bone density and marrow cellularity, particularly when considering short-range particle emitters localized to either the bone trabeculae or active marrow, respectively.
INTRODUCTION
One of the most important tissues of the human body for which radiation dose estimates are needed is the hematopoietically active bone marrow. At levels of radiation exposure associated with medical imaging -nuclear medicine, fluoroscopy, and computed tomography -image acquisition protocols should be optimized so as to maximize image quality while minimizing stochastic risk (e.g., leukemia induction). 1 At higher levels of radiation exposure associated with external total body irradiation or molecular radiotherapy, optimized treatment will result in the highest level of tumor dose while avoiding deterministic tissue reactions (e.g., marrow toxicity). 2, 3 Risk models for stochastic cancer risk are typically derived from radiation epidemiology studies of cohort members either exposed to external radiation fields (e.g., atomic bomb survivors) [4] [5] [6] or internalized radioactivity (e.g., workers at the Mayak Pu production facility and surrounding Southern Urals villages). [7] [8] [9] In each of these scenarios, estimates of radiation dose to active marrow would ideally be derived using customized computational models of bone marrow irradiation (e.g., individual patients or discrete cohort members). Unfortunately, the geometric complexity of the skeletal tissues -at both its macroscopic and microscopic level -presently precludes such an approach. As a result, medical and health physicists rely on reference models of skeletal dosimetry based on standardized tissue masses and dose schema from the International Commission on Radiological Protection (ICRP). [10] [11] [12] These reference skeletal dosimetry models, in turn, are based upon limited 2D or 3D image sets of bone microstructure acquired from a relatively few cadaveric bone specimens. [13] [14] [15] Consequently, one may question to what extent a reference skeletal dosimetry model can report accurate marrow doses in individual patients or members of the general public?
This study explores changes in reference active marrow dosimetry for three skeletal sites -lower ribs, L3 vertebra, and parietal bone -with respect to changes in individualspecific parameters: marrow cellularity (surrogate for agerelated increases in marrow adiposity), bone size (surrogate for patient stature), and trabecular bone volume fraction (TBVF) (surrogate for bone mineral density). Three boneseeking beta-particle emitters and three bone-seeking alpha-particle emitters are considered. Dosimetric parameters investigated include both the energy-dependent specific absorbed fraction to active bone marrow, and the radionuclide S value (marrow dose per decay in a given skeletal source tissue). The goal of this study was thus to explore what combinations of particle type, particle energy, source tissue, bone site, and varied parameter (marrow cellularity, bone size, or TBVF) would result in changes to active marrow dose that would be in excess of AE 10% of reference model dosimetry. In such cases, the development of a more parameterized skeletal dosimetry model applicable to the individual patients might be justified.
MATERIALS AND METHODS

2.A. Image-based dosimetry models of the skeleton
In 2016, O'Reilly 16 created a comprehensive electron skeletal model of the reference adult female as defined in ICRP Publications 70 11 and 89. 17 This model follows the study of Hough et al. for the reference adult male. 15 The O'Reilly model was based on studies of 37 excised bone sites from a 45-year-old female cadaver. Cored samples of trabecular spongiosa were imaged via microCT at 30 lm resolution. These bone microstructural images, coupled with ex vivo CT images of the bone macrostructure, were used for radiation transport of monoenergetic electrons in various source tissues to include bone marrow (active and inactive), trabecular bone (volume and surfaces), and cortical bone (volume and surfaces). Target tissues included both the active marrow and shallow marrow, defined as the surrogate tissue regions for marrow stem cells and osteoprogenitor cells, respectively. Bone macrostructural models were taken directly from the individual bones within the University of Florida (UF) hybrid computational phantom of the reference adult female. 18, 19 In the present study, the bone models of the lower ribs, L3 lumbar vertebra, and parietal bone of the cranium are taken from the O'Reilly model of the reference adult female. 16 These particular bone sites were chosen based upon two criteria: (1) relative high fractions of total bone active bone marrow, and (2) a wide variation in the bone trabecular microarchitecture. Figure 1 shows images of the cranium and parietal bone applied in this study.
2.B. Systematic changes in bone site parameters
The first parameter to be investigated was marrow cellularity. Following methods detailed in O'Reilly, 16 marrow cellularity (defined in our skeletal models as one minus the fat fraction of bone marrow) was varied in the microCT segmented images of the lower rib, L3 vertebrae, and parietal bone of the adult female. An in-house MATLAB TM script was used to systematically retag marrow voxels to match targeted values of marrow cellularity. Marrow cellularities were assessed at 10%, 20%, 40%, 60%, 80%, and 100%, as well as their ICRP reference cellularity (70% for the ribs and lumbar vertebrae, and 38% for the parietal bone pursuant to ICRP Publication 70 11 ). black, inactive marrow voxels in gray (i.e., adipocytes), and active marrow voxels in white.
The second parameter to be investigated was patient stature. This change was implemented by altering total bone volumes of each skeletal site by AE 5%, AE 10%, and AE 15% relative to their reference bone size. For each size change, fractional volumes of both cortical bone and spongiosa remained constant. Final volumes for all bone macrostructures, for each skeletal site, are shown in (Table I) . Skeletal sites were scaled in three dimensions within the NURBS and polygon mesh surface modeling software Rhinoceros TM (www.rhino3d.com) applying its 3D-scale command as demonstrated graphically in Fig. 3 .
The third parameter to be studied was bone mineral density as realized through changes in bone trabeculae thickness. Trabeculae thinning would thus be associated with either age-related or disease-induced osteopenia or osteoporosis. 20 In this study, bone trabeculae volumes were varied AE 5%, AE 10%, and AE 15% from their reference volumes. For positive volume changes, active marrow voxels sharing a face with trabecular bone voxels were retagged as bone voxels (with no preference to any single coordinate direction). Voxels were added until the total voxel count matched its targeted value. Conversely, for negative volume changes, trabecular bone voxels sharing a face with active marrow voxels were retagged as marrow voxels (again, with no preference to any single direction).
By retagging voxels at the bone/marrow interaction, bone trabeculae were effectively thickened and thinned based on the desired volume change. All trabecular bone retagging was performed in MATLAB TM on binary images at 100% cellularity. Following the voxel retagging procedure, marrow voxels were further retagged as inactive marrow to reestablish ICRP-defined marrow cellularity. Cross-sectional images of the L3 vertebrae at À15% and +15% bone trabeculae volumes are shown in Figs. 4(a) and 4(b) , respectively. 
2.C. Radiation transport simulations
All simulations were completed using the radiation transport code MCNPX v.2.7. 21 For monoenergetic electron simulations, an ICRP-defined energy grid of 10 keV to 10 MeV was utilized. For monoenergetic alpha particles, an energy range of 3-10 MeV in 0.5 MeV increments was applied. Particle histories were chosen to ensure relative tally errors below 1% for both skeletal macrostructure and microstructure simulations. Monoenergetic photon contributions to marrow dose were assessed using energy-dependent fluence tallies in the spongiosa of the bone macrostructural models and fluence-to-dose response functions as reported by Johnson et al.
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In the course of this study, spongiosa source regions investigated included the active marrow (AM), trabecular bone volume (TBV), and trabecular bone surfaces (TBS). Additionally, the cortical bone volume (CBV) was utilized as a source region when investigating the influence of bone size on active marrow dosimetry. Particle transport simulations were performed in which energy deposition (in MeV) was recorded in both regions of interest -spongiosa for CBV sources (see below), and active marrow for AM, TBV, and TBS sources.
2.D. Calculation of specific absorbed fractions and radionuclide S values
For each bone site macrostructure and microstructure geometry, the results of the energy deposition tallies were used to compute both absorbed fractions (AFs) and specific absorbed fractions (SAFs). The AF to the active marrow target ɸ (AM r S , E i ) is computed as:
where E deposited is the energy imparted in the target region, and E i is the initial energy of the particle in the source region r S . The SAF to active marrow UðAM r S ; E i Þ is then given as:
where m AM is the active marrow mass. It is noted that the mass of the entire target region is used in this normalization as the energy deposition is averaged across the entire marrow cavity. A second, but separate study has been undertaken in our laboratory to investigate the impact of observed spatial gradients in target cells within the marrow cavities. 23, 24 FIG. 3. Scaled macrostructure skeletal sites of the UF reference adult female phantom including (left to right) +15%, +10%, +5%, 0% (reference), À5%, À10%, and À15% changes in volume.
FIG. 4. L3 vertebrae with (a)
À15% volume change and (b) +15% volume change in trabecular bone volume (both at 100% marrow cellularity for clarity).
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Cortical bone volume was also included as a source tissue with the active marrow as the target in the investigation of changes in bone size (e.g., patient stature). To calculate the absorbed fraction from the CBV to active marrow, the following expression is used:
where / mac ðspongiosa CBV Þ is the AF from particle transport in the bone macrostructure and TBVF is the trabecular bone volume fraction of spongiosa. The parameter A is a combined, weighted AF given as:
where / mic ðAM AMÞ is the absorbed fraction for active marrow self-irradiation, / mic ðAM IMÞ is the absorbed fraction to active marrow from inactive marrow sources, / mic ðAM TBVÞ is the absorbed fraction to active marrow from trabecular bone volume sources and CF is the ICRP cellularity factor of the bone site. Eqs. 3 and 4 were originally developed by Pafundi et al. 25 and were demonstrated by O'Reilly 16 to yield results equivalent to those based upon the paired-image radiation transport (PIRT) methodology of Hough et al.
15,26
To compute the absorbed dose to active marrow over a given dose-integration period s, the MIRD schema may be used as defined below:
whereÃðr S ; sÞ is the time-integrated activity (i.e., total number of decays) in the source tissue over time s, and SðAM r S Þ is the radionuclide S value -the absorbed dose to active marrow per nuclear transformation in that source tissue. 27 The S value in turn is computed as:
where E i is the energy of the ith nuclear transition, and Y i is the number of nuclear transitions per nuclear transformation of the radionuclide of interest. S values in this study were computed via an in-house MATLAB TM script using values of particle energies and yields taken from ICRP Publication 107, 28 which include the full spectrum of beta-particle energies. Dose contributions by alpha-particle recoil nuclei were evaluated using extrapolated SAFs for 2-MeV alpha particles -an approach identical to that made by the ICRP in their Publication 133. 29 S values are reported here in the units of mGy per MBq-s. It is further noted that the focus of this study was on interpatient variability in marrow dose embodied in the radionuclide S value. Additional (and in many cases much larger) variations in marrow dosimetry can be associated with the biokinetics of the radionuclide or radiopharmaceutical from which estimates ofÃðr S ; sÞ are derived. 30 The present study is limited to investigations of changes in S values only.
RESULTS
In the sections that follow, graphical illustrations of our results are given only for the parietal bone of the cranium. Numerical data for all three bone sites are shown in data tables.
3.
A. Electron SAF dependence on marrow cellularity, bone size, and TBVF Electron SAFs for active marrow self-irradiation within the parietal bone are shown in Fig. 5 . As previously discussed both by Hough et al. 15 and by O'Reilly, 16 the only source-target combination which is significantly impacted by changes in marrow cellularity is active marrow self-irradiation. Variations in values of UðAM AM; E i Þ are shown to increase with decreasing electron energy and with decreasing marrow cellularity. Figure 6 next shows electron SAFs for irradiation of the active marrow from a CBV source in the parietal bone of the adult female at different bone sizes. In this irradiation scenario, the resulting SAFs are quite small and are orders of magnitude lower than for irradiation sources in the spongiosa tissues. Additionally, the resulting SAFs in Fig. 6 show a very small dependence on overall bone size. Finally, Fig. 7 displays electron SAFs for irradiation of the active marrow from a TBV source in the parietal bone of the adult female at different values of the TBVF (mimicking differences in bone mineral density). Similar trends are seen when the electron sources are on the surfaces of bone trabeculae (TBS sources). We discuss later in this paper corresponding changes in radionuclide S values.
3.B. Alpha-particle SAF dependence on marrow cellularity, bone size, and TBVF
Alpha-particle values of UðAM
AM; E i Þ in the parietal bone at varying marrow cellularities are shown in Fig. 8 . Similar to that seen for electron sources, alpha-particle SAFs are at a maximum at the lowest marrow cellularities and particle energies, after which they begin to converge with increasing particle energy. SAFs for a CBV source of alpha particles irradiating the active marrow at differing bone sizes are shown in Fig. 9 . Due to the smaller ranges of alpha particle in bone tissue, values of UðAM CBV ; E i Þ are shown to be 1-3 orders of magnitude lower than corresponding values for electron sources in the CBV. Finally, alpha-particle values of U AM TBV; E i ð Þare shown in Fig. 10 . Unlike those for long-range electrons in this same irradiation scenario, SAFs for the short-range alpha particles continue to diverge with increasing particle energy. Tables II, III , and IV show percent differences in radionuclide S values from those established at reference conditions of marrow cellularity, bone size, and TBVF, respectively. In this study, three beta-particle emitters are considered:
3.C. Radionuclide S value variations from reference model results
45 Ca, 153 Sm, and 90 Y with mean beta-particle energies of 77, 270, and 933 keV, respectively. Table II presents percent differences in S(AM AM, TBV, TBS) with changes in marrow cellularity, while Table III presents percent differences in S(AM AM, TBV, CBV) with changes in total bone volume. Finally, Table IV presents percent differences in S(AM AM, TBV, TBS) with changes in trabecular bone volume fraction. Corresponding data for the alpha-particle emitters 223 Ra, 219 Rn, and 215 Po are given in Tables V, VI , and VII, respectively. Three electronic annexes are provided giving absolute values of the radionuclide S value in units of mGy per MBq-s for the parietal bone, lower ribs, and L3 vertebra, respectively, for all radionuclides and source tissues considered in this study (see Data S1-S3).
DISCUSSION
4.A. Dosimetric impact of varying bone marrow cellularity
The data of Table II indicate that marrow cellularity does not have a major impact on active marrow dosimetry for internal beta-particle emitters localized to the surfaces or volumes of trabecular bone -values of S(AM TBS or TBV). For bone-seeking radionuclides, reference values of marrow cellularity may be assumed, even if they are not correct for a given patient. When these radionuclides are localized to the active marrow, however, knowledge of marrow cellularity can have a significant impact on errors in active marrow doses derived from reference models. For the beta-particles emitters of Table II , it is shown that dose errors are more pronounced for low-energy emitters than for high-energy emitters. For example, the percent difference in L3 TBS 1% 0% 0% 0% 0% 0%
Mean beta-particle energies are given in parentheses. Sm in the lumbar vertebra at 100% marrow cellularity is À5%, but at 10% cellularity, the difference is just short of 100%. For the alphaparticle emitters 223 Ra, 219 Rn, and 215 Po, the data of Table V show very similar trends, with very minimal errors in values of S(AM TBS or TBV), but with errors exceeding 200 to 300% for SðAM AMÞ in selected bone sites and at low values of marrow cellularity.
4.B. Dosimetric impact of varying bone size (individual stature)
The impact on reference active marrow S values with changes in bone size are shown in Table III for the beta-emitters and in Table VI for the alpha-emitters. In all cases, very minor changes in reference marrow dosimetry are indicated with alterations in bone size. For the lowest energy beta-particle emitter 45 Ca, active marrow doses ranged from 7% higher than reference doses for CBV sources in the ribs to 6% lower than reference doses for CBV sources in the lumbar vertebrae. For the highest energy beta-particle emitter 90 Y, active marrow doses ranged from 3% higher than reference doses for CBV sources in the cranium to 3% lower than reference doses for CBV sources in the lumbar vertebrae. For the alpha-emitters of Table VI, changes in bone size resulted had no impact to reference model marrow dosimetry with the single exception of CBV sources in the cranium, where a 5-6% increase in marrow dose was observed following a 15% decrease in total bone volume. In no case did active marrow S values deviate by more than 10% from reference dosimetry. Lumbar TBS 2% 1% 0% À1% À2% À3%
Mean beta-particle energies are given in parentheses. 
Energy ranges of the more prominent alpha particles are given in parentheses.
4.C. Dosimetric impact of varying TBVF (bone mineral density)
In our final parameter study, we vary the fraction of spongiosa occupied by trabecular bone (TBVF) in an attempt to mimic changes in bone mineral density from that in the UF reference skeletal model. Data for 45 Ca, 153 Sm, and 90 Y are given in Table IV, with corresponding data for 223 Ra and its two immediate progeny shown in Table VII . In this study, we introduce relative changes (up to AE15%) in the TBVF for each bone site. These relative changes correspond to major changes in absolute bone trabeculae volume for the parietal bone whose reference TBVF is 68%. This is in contrast to smaller absolute changes in trabecular bone volume for the lower ribs and L3 lumbar vertebrae whose reference TBVFs are only 9.1% and 12.6%, respectively. 16 As a result, changes in values of S(AM AM, TBV, TBS) for the latter two bone sites are generally only a few percent of reference S values. The one exception is for the low-energy beta-emitter 45 Ca, where values of SðAM TBVÞ are reduced from reference values by up to À15%. The data for the ribs also interestingly show reductions in marrow dosimetry from reference values with both positive and negative changes in TBVF. While trabecular bone is more or less uniformly found within the spongiosa of the parietal bone and lumbar vertebrae, it is found as isolated "islands" of trabecular bone within image slices of the ribs.
For each of the beta-emitting radionuclides considered, computed values of SðAM TBVÞ in the parietal bone are up to 60% lower than reference S values at an increase of +15% TBVF.
Conversely, computed values of SðAM TBVÞ in the parietal bone are shown to increase to 66% higher than reference S values at a change of À15% TBVF. For the alpha-emitter 223 Ra and its two immediate Energy ranges of the more prominent alpha particles are given in parentheses. Energy ranges of the more prominent alpha particles are given in parentheses.
progeny, percent differences in value of SðAM TBVÞ in the parietal bone range from À59% to +41% for equivalent changes in the TBVF.
4.D. Summary of individual variations
Tables VIII and IX below give a summary of the results derived from this study. Table VIII focuses on our  study of marrow cellularity, while Table IX focuses on our study of bone mineral density. A checkmark in any position indicates that the parameter change resulted in an S value difference equal to or greater than AE10% of reference dosimetry (defined as a "significant" change). As no percent differences in S values from the stature investigation yielded results above this threshold, no corresponding summary table is given.
For changes in marrow cellularity beyond ICRP reference values, active marrow dosimetry is impacted only for active marrow self-irradiation, and this was found to occur for all radionuclides considered, with the single exception of 90 Y. For this high-energy beta-emitter, active marrow self-irradiation was adequately assessed in the reference model for all bone sites and cellularities, with the possible exception of the parietal bone at very low marrow cellularities. For variations in the trabecular bone volume fraction (roughly indicating thickening or thinning of the bone trabeculae), no significant deviation from reference dosimetry were seen for SðAM AMÞ for all radionuclides and all bone sites, with two exceptions -
153
Sm and 90 Y in the parietal bone. For trabecular bone surface sources, values of SðAM TBSÞ did not deviate from reference dosimetry in either the lower ribs or L3 vertebrae for any of the radionuclides considered. In the parietal bone, deviations greater than AE10% were seen for SðAM TBSÞ for the three betaparticle emitters, but not for the alpha-particle emitters. Finally, the bone source demonstrating the greatest sensitivity to changes in TBVF was for the trabecular bone volume. With the exception of 153 Sm and 90 Y in the ribs and vertebrae, values of SðAM TBVÞ deviated from reference dosimetry in excess of AE10% for all other combinations of radionuclide and bone site. Check marks indicate a change in reference S value equal to or greater than AE 10%. MC -minimal change (defined as a percent difference < 10% of reference S values).
CONCLUSIONS
A method was presented in this study for assessing the variability of bone-specific radionuclide S values through variations in marrow cellularity, bone size, and bone mineral density. The study addresses to what extent is a single reference model of skeletal dosimetry applicable to individuals internally exposed to bone-seeking radionuclides. Electron and alpha-particle SAFs and corresponding radionuclide S values were computed for the parietal bone, lower ribs, and L3 vertebrae. Percent differences between reference model S values and S values following proportional changes marrow cellularity, bone size, and bone mineral density are given for the beta-emitting radionuclides 45 Ca, 153 Sm, and 90 Y, as well as the alpha-emitting radionuclide 223 Ra and its two immediate progeny, 219 Rn and 215 Po. This study is limited to the exploration of changes in radionuclide S values, and not active marrow dose per se, which would require further consideration of the type of radiopharmaceutical, the resultant changes in source tissues, consideration of biokinetics, and in the case of 223 Ra, the full consideration of all decay chain progeny. Another acknowledged limitation of this study is that all bone characteristics were adjusted as independent variables. For example, it has been shown that increases in marrow cavity space with osteoporotic thinning of the bone trabeculae are associated with increases in marrow fat content, and thus marrow cellularity declines and thus does not stay constant, with decreasing bone mineral density. 31 Study results indicate that the overall variability of the S value is highly contingent on the bone site, parameter varied, emission energy, and source-target geometry. S values for active marrow sources at different marrow cellularities are likely to greatly vary for marrow self-irradiation, but vary minimally for other source-target geometries. High variability in the radionuclide S value was seen in the parietal bone with relative changes in bone mineral density due to its inherently high proportion of trabecular bone. Corresponding differences were not seen in the lower rib and L3 vertebrae, which have much smaller spongiosa fractions of trabecular bone. Additionally, no variability above AE10% was seen in our study of changes in bone size, indicating that the role of patient stature is a very minor source of variability in reference marrow dosimetry. This study highlights the need for a more parameterized computational model of marrow dosimetry that permits as input patient-specific measurements of marrow cellularity (as determined by MR imaging) 32 and bone mineral density (as determined by dual-energy CT imaging). 33 Additionally, this and future studies can better inform us regarding uncertainties in marrow dosimetry used in radiation epidemiology studies.
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